AVACOPAN - Generic Drug Details

What are the generic drug sources for avacopan and what is the scope of freedom to operate?

Avacopan is the generic ingredient in one branded drug marketed by Chemocentryx and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Avacopan has one hundred and twenty-nine patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for AVACOPAN

International Patents:	129
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	27
Clinical Trials:	11
Patent Applications:	482
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AVACOPAN
What excipients (inactive ingredients) are in AVACOPAN?	AVACOPAN excipients list
DailyMed Link:	AVACOPAN at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AVACOPAN

Constraining patent/regulatory exclusivity:

8,906,938

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AVACOPAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Robert Spiera, MD	PHASE2
Amgen	PHASE2
Ottawa Hospital Research Institute	PHASE3

See all AVACOPAN clinical trials

Pharmacology for AVACOPAN

Drug Class	Complement 5a Receptor Antagonist
Mechanism of Action	Complement 5a Receptor Antagonists Cytochrome P450 3A4 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for AVACOPAN

L04AA	Selective immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

L04AJ	Complement inhibitors
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for AVACOPAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAVNEOS	Capsules	avacopan	10 mg	214487	3	2025-11-13

US Patents and Regulatory Information for AVACOPAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	8,445,515		Y	Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	11,951,214		Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	11,603,356		Y	Y

EU/EMA Drug Approvals for AVACOPAN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vifor Fresenius Medical Care Renal Pharma France	Tavneos	avacopan	EMEA/H/C/005523Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).	Authorised	no	no	yes	2022-01-11

International Patents for AVACOPAN

Country	Patent Number	Title	Estimated Expiration
European Patent Office	4233850
Hungary	E069633
Australia	2009330194
Japan	2017193586

Supplementary Protection Certificates for AVACOPAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2381778	LUC00258	Luxembourg		PRODUCT NAME: AVACOPAN ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT; AUTHORISATION NUMBER AND DATE: EU/1/21/1605 20220119
3508477	PA2022006,C3508477	Lithuania		PRODUCT NAME: AVAKOPANAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS ; REGISTRATION NO/DATE: EU/1/21/1605 20220111
3508477	PA2022006	Lithuania		PRODUCT NAME: AVAKOPANAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS ; REGISTRATION NO/DATE: EU/1/21/1605 20220111
2381778	2290502-0	Sweden		PRODUCT NAME: AVACOPAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/21/1605 20220119

AVACOPAN Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Avacopan?

Avacopan is a selective complement 5a receptor inhibitor developed by Chemocentryx. It targets complement-mediated vasculitis, particularly anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The drug’s market relies on multiple factors:

Regulatory Status and Approvals

• Approved in the US by the FDA in May 2021 for treating GPA (granulomatosis with polyangiitis) and MPA (microscopic polyangiitis).
• Regulatory submissions are ongoing or planned in Europe and other regions.
• Fast approval was supported by the Phase III ADVOCATE trial, which demonstrated significant efficacy in remission induction [1].

Market Size and Potential

• AAV affects approximately 3 per 100,000 people globally, with higher prevalence in North America and Europe.
• Estimated to reach a peak annual sales of $500 million to $1 billion in the US and Europe, based on prevalence and pricing assumptions.
• Currently, limited competition exists, mostly off-label treatments, including corticosteroids and immunosuppressants like cyclophosphamide and rituximab.

Competitive Landscape

• Rituximab (Rituxan) is the standard of care, with annual sales around $7 billion globally.
• Complement pathway inhibitors, specifically targeting C5a, are emerging as a differentiated approach.
• No other drugs specifically targeting the C5a receptor have received regulatory approval for AAV; belimumab and eculizumab target different complement components but are not indicated for vasculitis.

Pricing and Reimbursement

• Price point set between $30,000 and $50,000 per year, consistent with other biologics for rare diseases.
• Reimbursement is favorable in the US, driven by FDA approval and clinical efficacy data.

Market Penetration Factors

• Post-approval, market adoption hinges on clinician familiarity, insurance coverage, and distribution channels.
• Efforts include education on advantages over existing therapies, such as reduced steroid dependency and fewer immunosuppressive side effects.

What Is the Financial Trajectory for Avacopan?

Revenue Projections

• Initial US launch in 2022, with revenues projected to reach approximately $150 million in 2023, based on early adoption and market access.
• Growth rate predicted at 20-30% annually over the next five years, reaching $500 million to $700 million by 2027.
• European and Asian launches could add $200-$300 million in peak global sales, contingent on regulatory approvals.

Cost Structure

• Development costs totaled approximately $600 million, covering Phase I-III trials.
• Marketing and sales expenses are estimated at 30% of revenues post-launch.
• Manufacturing costs are under control due to the use of existing biologic production infrastructure.

Profitability Outlook

• Gross margins are closely aligned with biologics standards, near 80%.
• Profitability expected by 2025, once commercial scale and reimbursement are established.
• Ongoing investment in lifecycle management, including potential expansion into other complement-mediated diseases.

Risks Impacting Financial Performance

• Delays in regulatory approvals outside the US.
• Competitive emergence from pipeline drugs with similar mechanisms.
• Pricing pressures and insurance reimbursement changes.
• Possible safety concerns or adverse events impacting market confidence.

How Do Market and Financial Trends Compare with Similar Drugs?

Aspect	Avacopan	Rituximab	Eculizumab (Soliris)
Indication	AAV	B-cell lymphoma, rheumatoid arthritis, vasculitis	Paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Peak Sales	$500M-$1B	$7B globally	$4B globally
Price per Year	$30,000-$50,000	$30,000-$70,000	Over $500,000
Approval Date	2021 (US)	1997 (US)	2007 (US)

Avacopan’s trajectory aligns with the growth patterns of targeted biologics for rare autoimmune conditions, showing rapid uptick once approved, with sustained growth as awareness and clinician familiarity increase.

Key Takeaways

• Avacopan is positioned to capture a niche segment within rare vasculitis, with potential expansion.
• The drug’s market growth relies on regulatory approvals, clinician adoption, and reimbursement strategies.
• Sales projections suggest reaching up to $1 billion globally in the next five years.
• Competitive hurdles include existing therapies and future pipeline drugs.
• Financial performance depends on managing costs, optimizing manufacturing, and navigating reimbursement.

FAQs

1. When did Avacopan receive FDA approval?
May 2021.

2. What is the estimated peak global sales potential?
Between $800 million and $1.2 billion, contingent on regional approvals and market access.

3. Who are the main competitors to Avacopan?
Rituximab and off-label corticosteroids. No direct complement receptor inhibitors are yet marketed for AAV.

4. What are key risks for Avacopan’s financial outlook?
Regulatory delays, safety concerns, pricing pressures, and pipeline competition.

5. Are there plans for expanding Avacopan’s indications?
Possible expansion into other complement-mediated diseases, pending clinical trial results.

---

References

[1] Chemocentryx. "Avacopan Clinical Trial Data," 2021.